Reversal of Cognitive Decline in 100 Patients Using the Bredesen Protocol

by Amylee Amos PhD, RDN, IFMCPNews
Journal of Alzheimer’s Disease and Parkinsonism

Last month in the Journal of Alzheimer’s Disease and Parkinsonism, Dale Bredesen MD and practitioners from fifteen clinical sites in the United States and abroad published the first publication of its kind: documentation of 100 patients following the Bredesen Protocol who demonstrated a reversal of cognitive decline.

The Amos Institute is a proud contributor to this publication and we were thrilled to have some of our clients included in these exemplary published results. Our publication shows that the results of the Bredesen Protocol are not restricted to one physician or practitioner. The results of this protocol are not rare; rather, they are highly achievable and reproducible in a number of clinical sites, including the Amos Institute.

The study included patients with well documented cognitive decline. The patients within the study had varying degrees of cognitive decline and presented with various subtypes of Alzheimer’s disease. In the publication we document both subjective and objective improvement in all subtypes of Alzheimer’s disease (1).

Our approach is multi-targeted. Following the comprehensive, precision based parameters of the Bredesen Protocol, we identify the individual metabolic imbalances of each patient and use a systems based approach to treat each imbalance, identifying and treating the root cause of the imbalance, rather than masking the symptoms. Our result is the reversal of cognitive decline. This approach is revolutionary, and it is the exact opposite of the monotherapeutic, conventionally accepted gold standard approach of simply prescribing pharmaceuticals to treating Alzheimer’s disease.

Dr. Bredesen’s two previous publications delineate the reversal of symptoms in 10 patients each (2,3). When he first published his findings in 2014, they were the first of their kind. Though utterly groundbreaking, the study received criticism for the small sample size. This latest publication of 100 patients is hopefully a pivotal step in increasing awareness of the Bredesen Protocol and eliciting the respect and attention of the mainstream medical community. Additionally, demonstrating reversal of cognitive decline in 100 patients should provide the background needed to support future clinical trials.

Alzheimer's disease is currently the 3rd leading cause of death (4). It is an exponentially massive problem, that is ripping apart families and bankrupting our healthcare system. This latest publication shows the improvement of 100 patients, but in fact thousands more are improving behind the scenes. This is a treatment modality that works. Yet, if you visit the Alzheimer’s Association website, you will find under Myth #8 of Alzheimer's Disease that there is “ treatment to cure, delay or stop the progression of Alzheimer's disease.”(5)  We have documented that Alzheimer’s disease is both reversible and highly preventable. Only time will tell if wealthy organizations will accept that the answers are right in front of us.

I highly encourage you to read this latest publication. It provides tremendous hope to the millions of individuals suffering from or at risk of Alzheimer’s disease.  It also demonstrates the need to partner with a trained functional medicine practitioner. All of us who co-authored this publication have advanced training in functional medicine. If you have cognitive decline or have strong risk for Alzheimer's disease, contact the Amos Institute today.


  1. Bredesen, D.E., Sharlin, K., Jenkins, D., Okuno M., Youngberg, W., et al. (2018) Reversal of Cognitive Decline: 100 Patients. J Alzheimers Dis Parkinsonism 8: 450.
  2. Bredesen, D.E. (2014). Reversal of cognitive decline: a novel therapeutic program. Aging, 6(9): 707-719.
  3. Bredesen, D.E., et al. (2016). Reversal of cognitive decline in Alzheimer’s disease. Aging, 8(6): 1-9.
  4. James B.D., et al. (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology, 82: 1045-1050.
  5. Alzheimer’s Association (2018). Retrieved from: